Reata Scheduled to Attend Upcoming Investor Conferences
IRVING, Texas, Feb. 06, 2017 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (NASDAQ:RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with serious or life-threatening diseases, announced today that its senior management team will be presenting at the following investor conferences in the first half of 2017:
Canaccord Genuity Rare Disease Conference
- New York – February 7, 2017
Leerink Partners Global Healthcare Conference
- New York – February 15-16, 2017
Cowen & Co. Health Care Conference
- Boston – March 6-8, 2017
Barclays Capital Global Healthcare Conference
- Miami – March 14-16, 2017
Deutsche Bank Health Care Conference
- Boston – May 3-4, 2017
Jefferies Global Healthcare Conference
- New York – June 6-9, 2017
About Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in regulating cellular metabolism and inflammation. Our two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target important transcription factors, called Nrf2 and NF-κB, to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Contact: Reata Pharmaceuticals, Inc. (972) 865-2219 firstname.lastname@example.org http://news.reatapharma.com Investor Relations: The Trout Group Lee M. Stern, CFA (646) 378-2922 IR@reatapharma.com
Reata Pharmaceuticals, Inc.